Square Hospitals has reported Tk687 crore in revenue for the fiscal year 2024-25, with its profit surging by 34% to Tk62.65 crore compared to the previous year.
The financial results were disclosed in Square Pharmaceuticals' recently published FY25 annual report as the hospital is an associate of the pharma giant.
However, despite the robust growth, Square Hospitals did not declare any dividends for the year. Instead, it plans to focus on expansion, upgrading, and replacing existing equipment with modern ones, according to the annual report.
The 400-bed hospital serves as a major contributor to private healthcare services in the country. Its outpatient department can accommodate up to 2,500 patients daily, while its inpatient department has a capacity of 500 patients.
Square Pharmaceuticals, the country's leading drug manufacturer, holds a 49.94% stake in Square Hospitals, having invested Tk21 crore in the hospital to acquire 1.99 lakh shares of Tk1,000 each with a premium of Tk55.07.
Square Pharma
Square Pharmaceuticals has announced a Tk650 crore investment plan to expand its operations and product line, alongside declaring the highest dividend in its corporate history – a 120% cash payout for the 2024-25 fiscal year.
The board of Square Pharma has approved an investment of Tk650 crore to be used for balancing, modernisation, rehabilitation, and expansion, the purchase of capital machinery, and land acquisition. The company aims to boost its manufacturing capacity and introduce a new range of medicines, including biological and specialised treatments for cancer and chronic diseases.
Since the outbreak of Covid-19 in 2020, Square Pharma has already invested around Tk2,000 crore in land, machinery, and BMRE projects to meet the increasing domestic and global demand for pharmaceuticals.
Square Pharmaceuticals reported a 15% rise in consolidated net profit to Tk2,397 crore for FY25, driven by strong performances from its subsidiaries and associates. The company's consolidated earnings per share (EPS) stood at Tk27.04, while its net asset value (NAV) per share was Tk157.88 and net operating cash flow per share (NOCFPS) was Tk19.52.
These consolidated figures include contributions from its foreign subsidiary, Square Pharmaceuticals Kenya EPZ Ltd, its local subsidiary Square Lifesciences Ltd, and three associate companies – Square Textiles, Square Fashions, and Square Hospitals.
However, the company's standalone profit declined by 5% to Tk1,474 crore.
In the first quarter of FY26, its consolidated revenue grew by 22% to Tk2,159 crore and the consolidated net profit jumped by 22% to Tk740 crore.